Zhong-qi Cai, Wan-peng Li, Xi Chen, Chao Zhu, Xiao-ting Xie, Li Liu, Ying Zhao, Yan Huang, Yang Li
{"title":"[大蒜素对SCN5A-F1473S突变引起的钠电流下降的逆转作用]。","authors":"Zhong-qi Cai, Wan-peng Li, Xi Chen, Chao Zhu, Xiao-ting Xie, Li Liu, Ying Zhao, Yan Huang, Yang Li","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>This study was designed to test the allitridum (All) activity in correction of sodium current decrease caused by SCN5A-F1473S mutation in HEK293 cells. The result may provide a theoretical basis for screening of new drugs in the treatment of Brugada syndrome. We transferred SCN5A-F1473S channel plasmids into HEK293 cells in a transient transfection. All was administrated acutely and chronically using extracellular irrigation flow and co-culture model. The concentration of All was 30 μmol·L(-1). We used whole cell patch clamp technique in voltage clamp mode to record current and gating kinetics. In order to explore the rescue function of All on decreased sodium peak current, we used confocal microscopy and Western blot to detect the expression of channel proteins in the cell membrane. We found a significant increase in sodium peak current of the 30 μmol·L(-1) All HEK293 cells (269.8 ± 16.6 pA/pF, P < 0.01), almost closed to the current density of the control group(298.2 ± 17.5 p A/p F, P < 0.01). All allowed the steady-state inactivation of the channel to move toward a more positive direction (V(1/2, inact) returns to -79.5 ± 2.4 mV, P < 0.01). It also slowed the intermediate state inactivation of the channel (inactivation prolongated to 598.1 ± 22.6 ms, P < 0.01). Meanwhile, All increased distribution and expression of the channel protein in the cell membrane (compared to F1473S, P < 0.01). All caused an increase of current in SCN5A-F1473S mutation cells. We consider that the main mechanism may be related to the reduced channel inactivation by the drug with an improvement of the migration barrier of the mutational channel.</p>","PeriodicalId":35924,"journal":{"name":"药学学报","volume":"51 12","pages":"1852-7"},"PeriodicalIF":0.0000,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[The reverse effects of allitridum on sodium current decrease caused by SCN5A-F1473S mutation].\",\"authors\":\"Zhong-qi Cai, Wan-peng Li, Xi Chen, Chao Zhu, Xiao-ting Xie, Li Liu, Ying Zhao, Yan Huang, Yang Li\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This study was designed to test the allitridum (All) activity in correction of sodium current decrease caused by SCN5A-F1473S mutation in HEK293 cells. The result may provide a theoretical basis for screening of new drugs in the treatment of Brugada syndrome. We transferred SCN5A-F1473S channel plasmids into HEK293 cells in a transient transfection. All was administrated acutely and chronically using extracellular irrigation flow and co-culture model. The concentration of All was 30 μmol·L(-1). We used whole cell patch clamp technique in voltage clamp mode to record current and gating kinetics. In order to explore the rescue function of All on decreased sodium peak current, we used confocal microscopy and Western blot to detect the expression of channel proteins in the cell membrane. We found a significant increase in sodium peak current of the 30 μmol·L(-1) All HEK293 cells (269.8 ± 16.6 pA/pF, P < 0.01), almost closed to the current density of the control group(298.2 ± 17.5 p A/p F, P < 0.01). All allowed the steady-state inactivation of the channel to move toward a more positive direction (V(1/2, inact) returns to -79.5 ± 2.4 mV, P < 0.01). It also slowed the intermediate state inactivation of the channel (inactivation prolongated to 598.1 ± 22.6 ms, P < 0.01). Meanwhile, All increased distribution and expression of the channel protein in the cell membrane (compared to F1473S, P < 0.01). All caused an increase of current in SCN5A-F1473S mutation cells. We consider that the main mechanism may be related to the reduced channel inactivation by the drug with an improvement of the migration barrier of the mutational channel.</p>\",\"PeriodicalId\":35924,\"journal\":{\"name\":\"药学学报\",\"volume\":\"51 12\",\"pages\":\"1852-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"药学学报\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"药学学报","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
本研究旨在检测allitrium (All)活性对SCN5A-F1473S突变引起的HEK293细胞钠电流下降的纠正作用。该结果可为Brugada综合征治疗新药的筛选提供理论依据。我们将SCN5A-F1473S通道质粒瞬时转染到HEK293细胞中。采用细胞外灌流和共培养模型急性和慢性给药。All浓度为30 μmol·L(-1)。我们使用全细胞膜片钳技术在电压钳模式下记录电流和门控动力学。为了探讨All对钠峰电流降低的拯救作用,我们采用共聚焦显微镜和Western blot检测细胞膜中通道蛋白的表达。在30 μmol·L(-1)浓度下,HEK293细胞的钠峰电流(269.8±16.6 pA/pF, P < 0.01)显著增加,与对照组的电流密度(298.2±17.5 P a / P F, P < 0.01)接近。所有这些都允许通道的稳态失活向更积极的方向移动(V(1/2, inact)返回到-79.5±2.4 mV, P < 0.01)。它还减缓了通道的中间状态失活(失活时间延长至598.1±22.6 ms, P < 0.01)。同时,All增加了细胞膜通道蛋白的分布和表达(与F1473S相比,P < 0.01)。所有这些都导致SCN5A-F1473S突变细胞电流增加。我们认为其主要机制可能与药物减少通道失活和改善突变通道的迁移屏障有关。
[The reverse effects of allitridum on sodium current decrease caused by SCN5A-F1473S mutation].
This study was designed to test the allitridum (All) activity in correction of sodium current decrease caused by SCN5A-F1473S mutation in HEK293 cells. The result may provide a theoretical basis for screening of new drugs in the treatment of Brugada syndrome. We transferred SCN5A-F1473S channel plasmids into HEK293 cells in a transient transfection. All was administrated acutely and chronically using extracellular irrigation flow and co-culture model. The concentration of All was 30 μmol·L(-1). We used whole cell patch clamp technique in voltage clamp mode to record current and gating kinetics. In order to explore the rescue function of All on decreased sodium peak current, we used confocal microscopy and Western blot to detect the expression of channel proteins in the cell membrane. We found a significant increase in sodium peak current of the 30 μmol·L(-1) All HEK293 cells (269.8 ± 16.6 pA/pF, P < 0.01), almost closed to the current density of the control group(298.2 ± 17.5 p A/p F, P < 0.01). All allowed the steady-state inactivation of the channel to move toward a more positive direction (V(1/2, inact) returns to -79.5 ± 2.4 mV, P < 0.01). It also slowed the intermediate state inactivation of the channel (inactivation prolongated to 598.1 ± 22.6 ms, P < 0.01). Meanwhile, All increased distribution and expression of the channel protein in the cell membrane (compared to F1473S, P < 0.01). All caused an increase of current in SCN5A-F1473S mutation cells. We consider that the main mechanism may be related to the reduced channel inactivation by the drug with an improvement of the migration barrier of the mutational channel.
药学学报Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
1.20
自引率
0.00%
发文量
0
期刊介绍:
Acta Pharmaceutica Sinica B (APSB) is a bimonthly English peer-reviewed online journal in ScienceDirect, which publishes significant original research articles, communications and high quality reviews of recent advances. APSB encourages submissions from all areas of pharmaceutical sciences, including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics.
APSB is a part of the series Acta Pharmaceutica Sinica, which was founded in 1953. The journal is co-published by Elsevier B.V., in association with the Institute of MateriaMedica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.